Day Traders Tag icon

×
BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering. The company was founded in 2015 and plans to list on the Nasdaq under the symbol BIOA. BioAge Labs filed confidentially on May 31, 2024. Goldman Sachs, Morgan Stanley, Jefferies, and Citi are the joint bookrunners on the deal. No pricing terms were disclosed. The company’s lead drug Azelaprag, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials. Also Read: Newly Listed ...


In The news